Skip to main navigation
Skip to search
Skip to main content
Mayo Clinic Home
Home
Profiles
Departments/Divisions
Grants
Research output
Prizes
Search by expertise, name or affiliation
Effectiveness of Simeprevir Plus Sofosbuvir, with or Without Ribavirin, in Real-World Patients with HCV Genotype 1 Infection
HCV-TARGET Study Group
Hepatology
Gastroenterology and Hepatology
Research output
:
Contribution to journal
›
Article
›
peer-review
134
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Effectiveness of Simeprevir Plus Sofosbuvir, with or Without Ribavirin, in Real-World Patients with HCV Genotype 1 Infection'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine & Life Sciences
Simeprevir
100%
Sofosbuvir
90%
Ribavirin
70%
Hepacivirus
57%
Sustained Virologic Response
52%
Genotype
44%
Infections
29%
N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide
12%
Observational Studies
12%
telaprevir
11%
Fibrosis
11%
Cohort Studies
10%
Therapeutics
10%
Logistic Models
10%
Selection Bias
8%
North America
8%
Sleep Initiation and Maintenance Disorders
8%
Protease Inhibitors
8%
Exanthema
7%
Duration of Therapy
7%
Interferons
7%
Nausea
6%
Headache
6%
Fatigue
6%
RNA
5%
Demography
5%
Guidelines
5%
Weights and Measures
4%
Confidence Intervals
4%
Safety
4%